Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07768215

Miniature In-line Respirator

This first-in-human pilot study will test an investigational miniature breathing device called the Hope inVent. The device is a small, single-use, in-line respirator that connects to a breathing tube and uses compressed oxygen to help move air in and out of the lungs. It has no moving parts and is designed to provide short-term breathing support in situations where standard ventilators may not be available, such as emergencies, disasters, battlefield settings, transport, or ventilator shortages.

The study will enroll up to 5 brain-dead organ donors who are already receiving mechanical ventilation at the Gift of Life Donor Care Center at the Hospital of the University of Pennsylvania. Donors will only be included after authorization for organ donation and research has been obtained through standard procedures. Donors who may donate lungs or who have significant lung disease will not be included.

During the study, investigators will briefly replace the standard ventilator with the Hope inVent device for up to 15 minutes. The standard ventilator will remain immediately available, and the donor will be continuously monitored by the clinical and research teams. Investigators will measure whether the device can maintain acceptable breathing measures, including oxygen level and carbon dioxide level. They will also record breathing pressures and tidal volume, which is the amount of air delivered with each breath. If the device does not perform as expected or if any safety concern occurs, the donor will be returned immediately to the standard ventilator.

There is no direct benefit to the organ donor. Information from this study may help determine whether this type of simple, low-cost breathing device could be useful for future patients who need emergency or short-term ventilator support when standard ventilators are not available.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

1 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location contact

Andrew Mannes, M.D.

CONTACT

[email protected]

301-594-3427

About this study

Study Description:

Proof of Concept pilot study to support use of a miniature in-line patient respirator for patient ventilation needs.

Objectives:

Primary Objective:

To assess the effectiveness of the miniature respirator to ventilate intubated braindead research donors while maintaining respiratory measures within acceptable range.

Secondary Objective

The miniature respirator performs as designed and tested in a lung simulator.

Endpoints:

Primary Endpoint:

A binary variable equal to 1 ("success") if both of the following criteria are met (during the placement of the test device):

  • the respirator maintains the end tidal CO(2) between 35- and 45-mm Hg;

and

  • the O(2) saturation measured by pulse oximetry is > 94%.

Otherwise, the primary endpoint is equal to 0 ("failure").

Secondary Endpoints:

Binary variables equal to 1 ("success") if tidal volume and airway pressure settings (PEEP and maximum peak airway pressure) are within 30% of predicted values. Otherwise, the secondary endpoints are equal to 0 ("failure").

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • INCLUSION CRITERIA
  • Diagnosis of brain death
  • Provision of signed and dated informed consent form for organ donation and research by donor family or surrogate decisionmaker.
  • Male or female, with no age restriction (see size exclusion).
  • Decedent transferred to the Gift of Life at Penn Medicine Donor Care Center (study site) for routine organ donor management and organ recovery procedures.

Exclusion criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Brain-dead research donor will be excluded if their baseline CO(2) or pulse oximetry is out of the accepted range for the study (defined as end tidal CO(2) between 35- and 45-mm Hg and the O(2) saturation measured by pulse oximetry > 94%) while on optimized ventilation.
  • Brain-dead research donors with severe respiratory disease. This may include:
  • Bullous lung disease - noted on pre-op imaging or by history.
  • h/o pneumothoraces
  • h/o severe asthma, COPD, or other significant lung disease
  • Brain-dead research donors with morbid obesity (BMI >=40).
  • Brain-dead research donor body weight of < 25kg.
  • Potential Brain-dead lung transplant donors (as determined by Gift of Life Donor Program staff according to at the time of study site (Donor Care Center) admission)
  • Intraoperative arterial blood gas values outside the range of normal for pH, PaO2, PaCO2, HCO3, O2Sat as measured in pre-device ABG (while on optimized ventilation).

Acceptable range for Arterial Blood Gas (ABG values)

Parameter - pH / Range - 7.35-7.45

Parameter - PaO2 / Range - >=75 mm Hg

Parameter - PaCO2 / Range - 35-45 mm Hg

Parameter - HCO3 / Range - 22-26 mEq/L

Parameter - SpO2 / Range - 94-100

Treatment and study plan

Hope inVent

Device

The Hope inVent is an investigational, single-use, miniature in-line respirator designed to provide short-term ventilatory support for intubated individuals. The device is a 3D-printed, pressure-cycled, gas-powered respirator with no moving parts. It connects to the endotracheal tube breathing circuit and uses compressed oxygen as its power source. In this study, only the Green Hope inVent model will be used. The device cycles between fixed pressure settings: peak inspiratory pressure of 18 cm H2O and positive end-expiratory pressure of 6 cm H2O. Enrolled brain-dead research donors will be placed on the device once for up to 15 minutes, with continuous respiratory and physiologic monitoring. The donor will then be returned to the standard mechanical ventilator.

Primary outcomes

  1. Proportion of donors with successful ventilation and oxygenation during Hope inVent testing.

    Time frame: During device use, from connection of the Hope inVent device to removal, up to 15 minutes.

    Success is defined as maintaining both end-tidal carbon dioxide between 35 and 45 mm Hg and oxygen saturation by pulse oximetry greater than 94% during placement of the Hope inVent device. If either criterion is not met, or if device use is stopped early because of inadequate ventilation or oxygenation, the outcome is classified as failure.

Secondary outcomes

  1. Proportion of donors with tidal volume within 30% of predicted value

    Time frame: During device use, from connection of the Hope inVent device to removal, up to 15 minutes.

    Tidal volume will be measured using an in-line respiratory monitor while the donor is ventilated with the Hope inVent device. Each donor will be classified as a success if tidal volume is within 30% of the protocol-specified predicted value; otherwise, the donor will be classified as a failure.

  2. Proportion of donors with positive end-expiratory pressure within 30% of predicted value

    Time frame: During device use, from connection of the Hope inVent device to removal, up to 15 minutes

    Positive end-expiratory pressure will be measured using an in-line respiratory monitor during Hope inVent ventilation. Each donor will be classified as a success if positive end-expiratory pressure is within 30% of the protocol-specified predicted value; otherwise, the donor will be classified as a failure.

  3. Proportion of donors with maximum peak airway pressure within 30% of predicted value

    Time frame: During device use, from connection of the Hope inVent device to removal, up to 15 minutes

    Maximum peak airway pressure will be measured using an in-line respiratory monitor during Hope inVent ventilation. Each donor will be classified as a success if maximum peak airway pressure is within 30% of the protocol-specified predicted value; otherwise, the donor will be classified as a failure.

Study contacts

Contact information is provided by the study sponsor or research team.

Andrew J Mannes, M.D.

CONTACT

[email protected]

(301) 594-3427

Tracy S Williams, R.N.

CONTACT

[email protected]

(301) 448-5366

Sponsors and collaborators

Lead sponsor

National Institutes of Health Clinical Center (CC)

Nih

Registry information

Official study title

First-In-Human Trial of Miniature In-Line, Pressure-Cycled, Emergency Respirator Device in Human Organ Donors

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Aug 17, 2026
Registry last updated
Aug 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.